» Articles » PMID: 31179404

Characterization of Drug-like Chemical Space for Cytotoxic Marine Metabolites Using Multivariate Methods

Overview
Journal ACS Omega
Specialty Chemistry
Date 2019 Jun 11
PMID 31179404
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

In the last few decades, marine metabolites have been exploited to find commercially viable products in several areas. In this article, molecular descriptors [log , mass, total polar surface area (TPSA), H-bond donor, H-bond acceptor, and the number of rotatable bonds] for the marine-derived cytotoxic metabolites were calculated and compared with marketed anticancer drugs to understand their position in the drug-like space. Marine-based cytotoxic metabolites are divided into highly toxic (HT) and moderately toxic (MT) classes. The marketed anticancer drugs complied well with Lipinski's rule of five for all molecular descriptors. The majority of HT and MT metabolites complied solely with H-bond donors and a number of rotatable bonds with the Lipinski cutoff values. Hierarchical cluster analysis (HCA) and principal component analysis (PCA) were also performed using 73 molecular descriptors on an ensemble of highly cytotoxic or moderately cytotoxic marine metabolites and the marketed reference drugs. The HCA results showed that 12% of marine metabolites clustered with the marketed anticancer drugs and many of them had structural scaffold homology. The PCA results revealed the presence of a clear distinction between the cytotoxic marine metabolites and the marketed anticancer drugs. Results indicate that mass, TPSA, and log are the vital parameters and the careful optimization of these parameters for marine cytotoxic metabolites may generate more meaningful anticancer candidates in the future.

Citing Articles

In silico investigation of cannabinoids from leaves as a potential anticancer drug to inhibit MAPK-ERK signaling pathway and EMT induction.

Iqbal S, Matsabisa M In Silico Pharmacol. 2024; 12(1):41.

PMID: 38716440 PMC: 11074091. DOI: 10.1007/s40203-024-00213-4.


Effects of gamma-radiation on microbial, nutritional, and functional properties of Katimon mango peels: A combined biochemical and in silico studies.

Jabin T, Biswas S, Islam S, Sarker S, Afroze M, Paul G Heliyon. 2023; 9(11):e21556.

PMID: 38027912 PMC: 10665690. DOI: 10.1016/j.heliyon.2023.e21556.


5,8-Dimethyl-9-carbazole Derivatives Blocking hTopo I Activity and Actin Dynamics.

Ceramella J, Iacopetta D, Caruso A, Mariconda A, Petrou A, Geronikaki A Pharmaceuticals (Basel). 2023; 16(3).

PMID: 36986453 PMC: 10051477. DOI: 10.3390/ph16030353.


Volatile Organic Compounds (VOCs) Protect from Fish Pathogen sp.: A Combined In Vitro, In Vivo, and In Silico Approach.

Mahmud M, Islam S, Biswas S, Mortuza M, Paul G, Uddin M Microorganisms. 2023; 11(1).

PMID: 36677466 PMC: 9862385. DOI: 10.3390/microorganisms11010172.


In silico activity and ADMET profiling of phytochemicals from Ethiopian indigenous aloes using pharmacophore models.

Bultum L, Tolossa G, Kim G, Kwon O, Lee D Sci Rep. 2022; 12(1):22221.

PMID: 36564437 PMC: 9789083. DOI: 10.1038/s41598-022-26446-x.


References
1.
Kelder J, Grootenhuis P, Bayada D, Delbressine L, Ploemen J . Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm Res. 1999; 16(10):1514-9. DOI: 10.1023/a:1015040217741. View

2.
Ghose A, Viswanadhan V, Wendoloski J . A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem. 2000; 1(1):55-68. DOI: 10.1021/cc9800071. View

3.
Lipinski C, Lombardo F, Dominy B, Feeney P . Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001; 46(1-3):3-26. DOI: 10.1016/s0169-409x(00)00129-0. View

4.
Veber D, Johnson S, Cheng H, Smith B, Ward K, Kopple K . Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002; 45(12):2615-23. DOI: 10.1021/jm020017n. View

5.
Dorr R . Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics. Semin Oncol. 1992; 19(2 Suppl 5):3-8. View